Galenica Pharmaceuticals Inc.
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Galenica Pharmaceuticals Inc.
Scrip 100: The Architecture Of A Top Heavy Industry
Pharmaceutical revenues were down slightly; so was R&D spending, thanks to a strengthening dollar. Scrip analyzes 620 companies and uses numbers, clocks and tiers to paint some data pictures of the pharmaceutical industry in 2015.
2016 Pharma Dealmaking: Waiting On The High-Value Deals
Six pharma deals announced thus far in 2016 carried up-front values of $1 billion or more, down considerably from the high-volume, high-value M&A industry experienced the prior two years. Pharma manufacturers appear to be recalibrating – digesting previous acquisitions, adjusting to new biotech valuations and taking stock of the political and macro-economic climate – but fundamentals suggest pharma dealmaking will pick up. Pfizer’s $14 billion offer for Medivation might represent a turning point.
Amgen Q2 Sales Rise, But Growth Depends On Repatha And Beyond
Execs faced questions about commercial preparations and potential label for Amgen’s PCSK9 inhibitor, we well as speculation about what the appointment of former Schering CEO Fred Hassan to the board means for Amgen’s M&A strategy.
Will Velphoro’s Convenience Advantage Be Enough In Crowded ESRD Field?
With the field going generic and a new brand competitor with additional advantages on the way, Vifor Pharma is counting on lower pill burden to propel hyperphosphatemia drug Velphoro.
Company Information
- Industry
- Biotechnology
-
Pharmaceuticals
- Vaccines
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice